Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Prostate Cancer
PROSTATE CANCER ADVISOR
FEATURED CONTENT
-
-
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated. -
PSA and Prostate Cancer Mortality: What’s the Link?
Has PSA screening led to overdiagnosis and overtreatment of a condition that may not actually cause any symptoms or lead to death? -
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions. -
Ipilimumab May Help Some Patients With Prostate Cancer—Even Those With Low TMB
A trial in phase 2 metastatic prostate cancer shows that some patients likely to benefit from ipilimumab treatment, even with low number of tumor mutations.
Current Research Into Pain Assessment
Immunotherapy for Prostate Cancer
Targeted Agents
Targeted Agents (cont.)
Radium-223
Chemotherapy
Immunotherapy
Treatment Sequencing
Androgen Deprivation Therapy
Duration of ADT
Docetaxel in Combination With ADT
HSD3B1 Allele Inheritance Linked With ADT Resistance
ADT and Radiation
Predictions for the Future
PROSTATE CANCER NEWS
Prioritizing Urologic Cancer Cases During the COVID-19 Pandemic
Local-Stage Prostate Cancer Incidence Rates Continue to Drop
PARP Inhibitor Approved for BRCA-Mutated mCRPC
Carboplatin Possibly Beneficial in Refractory mCRPC
Study Identifies Death Risk Predictors Among Men With Recurrent Prostate Cancer
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
